Stem Cells Therapy
Myocardial Infarction
(MI, Heart Attack)

Regenerate. Repair. Restore.

Schedule Your Free Phone Consultation

If you are considering stem cell therapy, contact the Stem Cells Transplant Institute today

A myocardial infarct, also called a heart attack or MI, is a life-threatening emergency, and occurs when the blood supply to the heart is suddenly blocked. “Myo” means muscle, “cardial” means relating to the heart, and “infarct” is a small localized area of dead tissue resulting from failure of blood supply.

The Stem Cells Transplant Institute offers a safe, non-surgical treatment for the repair of the ischemic damage that occurs from a heart attack.

What causes a myocardial infarct (heart attack)?

Coronary artery disease is the leading cause of heart attacks. Coronary artery disease is the buildup of plaque, causing a narrowing or blocking the blood vessels in the coronary arteries.

Coronary arteries carry oxygen rich blood to the heart. Plaque is caused by the presence of cholesterol, calcium, fat, and other substances in the blood.

When plaque builds up in the blood vessels it narrows the arteries causing them to harden and weaken, reducing the amount of oxygen rich blood to the heart.

If the plaque building up in the coronary arteries breaks, a blood clot forms around the plaque. If the clot cuts off the blood flow to the heart muscle completely, the heart muscle is unable to get the necessary oxygen and nutrients causing a part of the heart muscle to die. 

The result is a heart attack or myocardial infarction.

Although rare, other causes of myocardial infarction include:

It takes about 6-8 weeks for the heart to heal the damaged area. 

A scar will form where the damage occurred and that area will no longer contract, reducing the heart’s ability to pump. 

How severely the heart is permanently damaged depends on the location and size of the scar.

How can stem cell therapy improve hear function?

Stem cell transplantation uses healthy cells to promote the repair of damaged cells and regeneration of healthy and functional cells to repair injured tissue.

The therapeutic effect of stem cell transplantation in patients following a heart attack may be due to the paracrine effect.

The theory is transplanted stem cells repair damaged tissue by releasing factors that promote regeneration of healthy stem cells, reduce inflammation, promote the growth of new blood vessels, inhibit cell death, and reduce hypertrophy.1

What are scientists researching?

According to (, currently there are more than 90 trials evaluating stem cell therapy for the treatment of myocardial infarction.
Initial research using mesenchymal stem cell transplantation shows stem cell therapy can:

Adipose derived stem cells improve left ventricular function, promote angiogenesis, lower fibrosis, and decrease inflammation.

Several months following treatment, stem cells continue to migrate to the heart muscle regenerating and renewing healthy heart function. 

Stem cell therapy cannot help all patients, but for many patients stem cell therapy combined with lifestyle modification may be a safe, effective, non-surgical alternative treatment.

Lifestyle changes that can help reduce the risk of a second heart attack:

What is the treatment protocol for myocardial infarction at the Stem Cells Transplant Institute?

For optimal results, the Stem Cells Transplant Institute recommends the use of hUC-MSCs for the treatment of MI.

If the patient prefers, autologous mesenchymal stem cells derived from the patient’s own adipose tissue and bone marrow, can also be used to treat myocardial infarction.

Treatment includes:

  1. 1cc vial of mesenchymal stem cells derived from human umbilical cord blood or bone marrow and adipose derived, autologous mesenchymal stem cells
  2. Antioxidant therapy with vitamin C and glutathione
  3. Ozone therapy
  4. Platelet-rich plasma therapy (PRP)

What are the advantages of human umbilical cord mesenchymal stem cells?

How are the stem cells collected?

Umbilical cord stem cells

We use only umbilical cord stem cells that are derived exclusively from umbilical cord donations. 

The umbilical cord stem cells from are collected after informed consent has been given by the parent, or parents, and only after the delivery of the baby.

The collection follows strict ethical protocols ensuring the stem cells are from safe, reliable sources using a non-invasive, simple and painless procedure. Once collected, the cord blood is then screened for disease.

Autologous adipose and bone marrow stem cells

On the day of the procedure, under local anesthesia and sterile conditions, a small sample of bone marrow is removed from the hip and a small of amount of adipose tissue (fat) is removed from the abdomen.

How are the stem cells administered?

The stem cells are administered intravenously.

About the Stem Cells Transplant Institute

Costa Rica has one of the best healthcare systems in world and is ranked among the highest for medical tourism.

Using the most advanced technologies, the team of experts at The Stem Cells Transplant Institute believes in the potential of stem cell therapy for the treatment of myocardial infarction.

We are committed to providing personalized service and the highest quality of care to every patient.

Contact us to see if stem cell therapy may be a treatment option for you.

Scientific Reference:

  1. Sun R.Advances in stem cell therapy for cardiovascular disease (Review). National Journal of Mol. Med. 38: 23-29, 2016.
  2. Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease Luqia Hou,1,2 Am J Physiol Heart Circ Physiol 310: H455–H465, 2016.
  3. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C,  Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A. Comparison of allogeneic vs autologous bone marrowderived  mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308: 2369–2379, 2012.